Alzheimer’s Drug Discovery Foundation (ADDF) – Letter of intent

Preclinical Drug Discovery: Seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging. Funding: $150,000-$600,000 for 1/2 years.

Program to Accelerate Clinical Trials: Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials. Funding: Up to $1.5 million.

Biomarkers Development: Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. Funding: $150,000-$300,000/year for 1/2 years.

http://www.alzdiscovery.org/research-and-grants/request-for-proposal